An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. ICIs have shown great promise in the treatment of several advanced malignancies. However, therapy with these immunomodulatory antibodies may lead to a wide spectrum...

Full description

Bibliographic Details
Main Authors:	Roberta Esposito, Teresa Fedele, Silvia Orefice, Vittoria Cuomo, Maria Prastaro, Mario Enrico Canonico, Federica Ilardi, Francesco De Stefano, Ludovica Fiorillo, Ciro Santoro, Giovanni Esposito
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Biomolecules
Subjects:	myocarditis cancer immune checkpoint inhibitors immune-related adverse events cardio-oncology
Online Access:	https://www.mdpi.com/2218-273X/11/6/785

Similar Items

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
by: Robert S. Zhang, et al.
Published: (2021-03-01)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
by: Nikhil Agrawal, et al.
Published: (2019-03-01)

Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice
by: Siqi Li, et al.
Published: (2021-01-01)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
by: Jessica Castrillon Lal, et al.
Published: (2021-05-01)

Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT
by: Daniel Finke, et al.
Published: (2021-02-01)

Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis
by: Yunwei LIU, et al.
Published: (2021-09-01)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
by: Xiaoxiao Guo, et al.
Published: (2020-02-01)

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management
by: Muhammet Gürdoğan, et al.
Published: (2020-07-01)

Smoldering myocarditis following immune checkpoint blockade
by: Timothy G. Norwood, et al.
Published: (2017-11-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
by: Mariana Mirabel, MD, PhD, et al.
Published: (2020-09-01)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
by: Feifei Wang, et al.
Published: (2021-07-01)

Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center
by: Nida Waheed, et al.
Published: (2021-03-01)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients
by: Mandar A. Aras, MD, PhD, et al.
Published: (2020-09-01)

Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis
by: Stéphane Ederhy, et al.
Published: (2021-05-01)

Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
by: Rulan Ma, et al.
Published: (2021-01-01)

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
by: Melissa Y.Y. Moey, MD, MSc, et al.
Published: (2020-09-01)

Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Ming Yuan, et al.
Published: (2021-10-01)

Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy
by: Robin Jacob, MD, et al.
Published: (2020-11-01)

A systematic review of myasthenia gravis complicated with myocarditis
by: Wei Cheng, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
by: Shirley Xu, et al.
Published: (2021-02-01)

Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
by: Whitney Barham, et al.
Published: (2021-02-01)

Myocarditis in 2020
by: Tahir S. Kafil, MD, et al.
Published: (2020-02-01)

Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery
by: Ashley F. Stein‐Merlob, et al.
Published: (2021-10-01)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
by: Frederik Uttenthal Larsen, MD, et al.
Published: (2019-06-01)

The Tale of a Double-Edged Sword
by: Giselle A. Suero-Abreu, MD, PhD, et al.
Published: (2019-06-01)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
by: Osnat Itzhaki Ben Zadok, MD, MS, et al.
Published: (2019-09-01)

Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study
by: Roberta Noseda, et al.
Published: (2020-11-01)

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases
by: Emma Matzen, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
by: Yu-Wen Zhou, et al.
Published: (2019-11-01)

Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
by: Benjamin Shibru, et al.
Published: (2021-07-01)

Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor
by: Xiaoxiao GUO, et al.
Published: (2019-10-01)

CYTOKINE PROFILE OF Th1-, Th2- AND Th17-LYMPHOCYTE SUBPOPULATIONS IN INFECTIOUS MYOCARDITIS
by: N. P. Sanina, et al.
Published: (2016-02-01)

Cardiovascular Health during and after Cancer Therapy
by: Kathryn J. Ruddy, et al.
Published: (2020-12-01)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
by: Vanina Vani, et al.
Published: (2020-04-01)

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
by: Francesco Fiorica, et al.
Published: (2021-05-01)

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges
by: Martin Huertas R, et al.
Published: (2019-05-01)